NLS Long Term Debt vs Net Invested Capital Analysis

NLSPW Stock  USD 0.01  0  27.27%   
NLS Pharmaceutics financial indicator trend analysis is infinitely more than just investigating NLS Pharmaceutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NLS Pharmaceutics is a good investment. Please check the relationship between NLS Pharmaceutics Long Term Debt and its Net Invested Capital accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

Long Term Debt vs Net Invested Capital

Long Term Debt vs Net Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NLS Pharmaceutics Long Term Debt account and Net Invested Capital. At this time, the significance of the direction appears to have strong relationship.
The correlation between NLS Pharmaceutics' Long Term Debt and Net Invested Capital is 0.66. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of NLS Pharmaceutics AG, assuming nothing else is changed. The correlation between historical values of NLS Pharmaceutics' Long Term Debt and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of NLS Pharmaceutics AG are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Long Term Debt i.e., NLS Pharmaceutics' Long Term Debt and Net Invested Capital go up and down completely randomly.

Correlation Coefficient

0.66
Relationship DirectionPositive 
Relationship StrengthSignificant

Long Term Debt

Long-term debt is a debt that NLS Pharmaceutics has held for over one year. Long-term debt appears on NLS Pharmaceutics AG balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on NLS Pharmaceutics AG balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Net Invested Capital

The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.
Most indicators from NLS Pharmaceutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NLS Pharmaceutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
At this time, NLS Pharmaceutics' Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to climb to about 1.1 B in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

NLS Pharmaceutics fundamental ratios Correlations

-0.330.08-0.040.89-0.78-0.460.070.96-0.25-0.25-0.330.960.22-0.340.30.140.62-0.630.420.990.610.530.13-0.310.46
-0.33-0.82-0.81-0.40.840.82-0.87-0.13-0.4-0.371.0-0.13-0.50.99-0.97-0.55-0.820.670.66-0.260.45-0.7-0.70.91-0.8
0.08-0.820.990.03-0.56-0.80.99-0.110.520.51-0.83-0.110.56-0.830.870.610.76-0.15-0.790.02-0.680.680.45-0.860.86
-0.04-0.810.99-0.05-0.49-0.730.99-0.230.590.58-0.83-0.230.5-0.820.870.570.68-0.13-0.86-0.11-0.760.60.49-0.850.81
0.89-0.40.03-0.05-0.82-0.310.060.92-0.15-0.17-0.390.92-0.03-0.420.4-0.090.57-0.730.420.890.630.320.39-0.320.39
-0.780.84-0.56-0.49-0.820.74-0.58-0.65-0.14-0.110.84-0.65-0.360.84-0.82-0.35-0.870.810.15-0.73-0.1-0.69-0.590.76-0.77
-0.460.82-0.8-0.73-0.310.74-0.79-0.240.00.010.82-0.24-0.860.81-0.8-0.86-0.930.50.54-0.440.35-0.98-0.190.71-0.82
0.07-0.870.990.990.06-0.58-0.79-0.120.550.53-0.88-0.120.53-0.870.910.590.75-0.22-0.820.0-0.690.650.53-0.880.85
0.96-0.13-0.11-0.230.92-0.65-0.24-0.12-0.32-0.32-0.141.00.01-0.150.14-0.090.47-0.520.620.970.780.320.08-0.120.29
-0.25-0.40.520.59-0.15-0.140.00.55-0.321.0-0.43-0.32-0.32-0.420.43-0.210.00.07-0.54-0.35-0.56-0.160.7-0.670.39
-0.25-0.370.510.58-0.17-0.110.010.53-0.321.0-0.4-0.32-0.32-0.390.4-0.21-0.010.1-0.53-0.35-0.55-0.160.67-0.650.38
-0.331.0-0.83-0.83-0.390.840.82-0.88-0.14-0.43-0.4-0.14-0.491.0-0.98-0.54-0.820.660.66-0.260.46-0.69-0.690.93-0.82
0.96-0.13-0.11-0.230.92-0.65-0.24-0.121.0-0.32-0.32-0.140.01-0.150.14-0.090.47-0.520.620.970.780.320.08-0.120.29
0.22-0.50.560.5-0.03-0.36-0.860.530.01-0.32-0.32-0.490.01-0.460.460.980.68-0.25-0.490.23-0.380.91-0.23-0.320.5
-0.340.99-0.83-0.82-0.420.840.81-0.87-0.15-0.42-0.391.0-0.15-0.46-0.99-0.51-0.830.660.64-0.270.44-0.68-0.690.92-0.82
0.3-0.970.870.870.4-0.82-0.80.910.140.430.4-0.980.140.46-0.990.510.85-0.56-0.650.24-0.440.670.68-0.910.85
0.14-0.550.610.57-0.09-0.35-0.860.59-0.09-0.21-0.21-0.54-0.090.98-0.510.510.66-0.23-0.590.14-0.480.87-0.18-0.40.56
0.62-0.820.760.680.57-0.87-0.930.750.470.0-0.01-0.820.470.68-0.830.850.66-0.55-0.340.59-0.130.890.31-0.710.86
-0.630.67-0.15-0.13-0.730.810.5-0.22-0.520.070.10.66-0.52-0.250.66-0.56-0.23-0.550.05-0.61-0.18-0.47-0.50.48-0.36
0.420.66-0.79-0.860.420.150.54-0.820.62-0.54-0.530.660.62-0.490.64-0.65-0.59-0.340.050.480.96-0.4-0.380.65-0.49
0.99-0.260.02-0.110.89-0.73-0.440.00.97-0.35-0.35-0.260.970.23-0.270.240.140.59-0.610.480.660.520.05-0.220.4
0.610.45-0.68-0.760.63-0.10.35-0.690.78-0.56-0.550.460.78-0.380.44-0.44-0.48-0.13-0.180.960.66-0.23-0.230.48-0.32
0.53-0.70.680.60.32-0.69-0.980.650.32-0.16-0.16-0.690.320.91-0.680.670.870.89-0.47-0.40.52-0.230.03-0.570.73
0.13-0.70.450.490.39-0.59-0.190.530.080.70.67-0.690.08-0.23-0.690.68-0.180.31-0.5-0.380.05-0.230.03-0.720.39
-0.310.91-0.86-0.85-0.320.760.71-0.88-0.12-0.67-0.650.93-0.12-0.320.92-0.91-0.4-0.710.480.65-0.220.48-0.57-0.72-0.88
0.46-0.80.860.810.39-0.77-0.820.850.290.390.38-0.820.290.5-0.820.850.560.86-0.36-0.490.4-0.320.730.39-0.88
Click cells to compare fundamentals

NLS Pharmaceutics Account Relationship Matchups

NLS Pharmaceutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets696.4K1.2M5.8M9.3M1.8M3.3M
Short Long Term Debt Total7.1M842.1K2.1M1.6M1.5M1.4M
Other Current Liab835.7K1.4M666.4K986.4K1.7M1.0M
Total Current Liabilities4.0M7.2M2.4M3.4M7.9M4.5M
Total Stockholder Equity(6.2M)(9.0M)542.4K3.3M(8.8M)(9.3M)
Net Debt621.9K2.0M(5.4M)(8.9M)736.1K772.9K
Retained Earnings(26.9M)(29.8M)(41.7M)(58.2M)(70.4M)(66.9M)
Accounts Payable2.5M4.0M1.7M2.4M4.6M2.7M
Cash220.3K93.7K5.4M8.9M897.7K852.8K
Non Current Assets Total314.7K1.0M41.6K30.2K23.6K22.4K
Non Currrent Assets Other260.2K946.9K12.0K12.1K16.9K16.0K
Cash And Short Term Investments220.3K93.7K5.4M8.9M897.7K852.8K
Common Stock Shares Outstanding11.1M4.8M14.7M19.7M38.2M40.1M
Liabilities And Stockholders Equity696.4K1.2M5.8M9.3M1.8M3.3M
Non Current Liabilities Total2.8M3.0M2.8M2.6M2.8M3.4M
Other Current Assets86.1K14.4K292.0K191.0K914.7K960.5K
Other Stockholder Equity20.6M20.6M42.1M60.9M61.0M35.5M
Total Liab6.9M10.2M5.2M6.0M10.7M6.6M
Net Invested Capital(5.3M)(6.9M)542.4K3.3M(7.2M)(6.8M)
Total Current Assets381.7K196.7K5.7M9.2M1.8M3.1M
Accumulated Other Comprehensive Income(18.7K)(19.4K)(151.7K)(50.8K)(158.1K)(150.2K)
Net Working Capital(3.7M)(7.0M)3.3M5.9M(6.1M)(5.8M)
Net Receivables75.4K61.2K38.6K41.2K10.7K10.1K
Inventory(33.6K)(61.2K)(38.6K)(41.2K)(37.1K)(39.0K)
Short Term Debt690.1K1.8M2.5B1.6M1.9M1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.